FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, namely to a PD-1-chimeric cytokine receptor containing: ectodomain PD-1, a transmembrane domain of thrombopoietin receptor (TpoR), a Janus kinase (JAK) binding domain and a STAT attracting domain, as well as a polynucleotide coding it. Also disclosed is a vector and a cell containing said polynucleotide, as well as a method for producing said cell. Invention also relates to a kit and a pharmaceutical composition containing said cell.
EFFECT: invention is effective for treating cancer.
57 cl, 17 dwg, 11 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BCMA-SPECIFIC CHIMERIC ANTIGEN RECEPTORS CONTAINING IL-6 SIGNALLING BLOCKER | 2023 |
|
RU2828294C1 |
| BISPECIFIC ANTIBODIES AND THEIR APPLICATIONS | 2022 |
|
RU2821577C2 |
| MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR-BINDING DOMAIN OF SARS-COV-2 SPIKE PROTEIN AND THEIR ANTIGEN-BINDING FRAGMENTS ENCODING THEIR NUCLEIC ACIDS, AS WELL AS METHODS OF THEIR USE | 2021 |
|
RU2800649C2 |
| MUS MUSCULUS 5B9 HYBRID CULTIVATED ANIMAL CELLS- A PRODUCER OF MOUSE MONOCLONAL ANTIBODY 5B9, MONOCLONAL MOUSE ANTIBODY 5B9 AND RECOMBINANT CHIMERIC (MOUSE-HUMAN) ANTIBODY XI5B9, NEUTRALIZING RICIN RICINUS COMMUNIS | 2022 |
|
RU2802436C1 |
| NEW CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS CONTAINING TNFR2 DOMAINS | 2019 |
|
RU2808254C2 |
| BCMA HEAVY CHAIN ANTIBODIES | 2018 |
|
RU2816994C2 |
| MONOCLONAL ANTIBODY IC2 AND ITS ANTIGEN-BINDING FRAGMENT, SELECTIVELY BINDING RECEPTOR-BINDING DOMAIN OF SPIKE PROTEIN OF SARS-CoV-2 VIRUS, HAVING VIRUS-NEUTRALIZING ACTIVITY | 2023 |
|
RU2817697C1 |
| NUCLEOTIDE SEQUENCE CODING LYTICASE ENZYME, AND PANEL OF OLIGONUCLEOTIDES FOR OBTAINING SYNTHETIC NUCLEOTIDE SEQUENCE OF LYTICASE GENE | 2023 |
|
RU2826150C1 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| MONOCLONAL ANTIBODIES SPECIFIC TO PROTEIN RUSTICYANIN, AND USE OF ANTIBODIES FOR DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS | 2024 |
|
RU2823344C1 |
